Analysis Tools
mortality/aging
|
• lifespan after pIpC treatment is shorter than in controls but longer than in mutant nice with one wild-type Pkn3 allele
|
neoplasm
|
• develop myeloproliferative neoplasms in the spleen 2 weeks after pIpC treatment
|
|
• all eventually develop T cell acute lymphoblastic leukemia after pIpC treatment at 6 weeks of age
|
hematopoietic system
|
• at 2 weeks after pIpC treatment
• thymus is smaller than in mutant mice with one wild-type Pkn3 allele
|
|
• at 2 weeks after pIpC treatment
|
|
• increase in the number of hematopoietic stem cells in the spleen 2 weeks after pIpC treatment
|
endocrine/exocrine glands
|
• at 2 weeks after pIpC treatment
• thymus is smaller than in mutant mice with one wild-type Pkn3 allele
|
immune system
|
• at 2 weeks after pIpC treatment
• thymus is smaller than in mutant mice with one wild-type Pkn3 allele
|
|
• at 2 weeks after pIpC treatment
|
growth/size/body
|
• at 2 weeks after pIpC treatment
|
